Losartan Potassium Tablet, Film Coated
Product Images NDC 70518-2132

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 70518-2132). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Losartan Potassium 25mg 70518 2132 01

Losartan Potassium 25 mg film-coated tablets packaging label from RemedyRepack Inc. The label shows a quantity of 90 tablets, with manufacturer listed as Aurobindo Pharma, Hyderabad, India. It includes storage instructions and a barcode with NDC number 70518-2132-01.*

FDA Label Image

Losartan Potassium 25mg 70518 2132 02

Losartan Potassium 25 mg film-coated tablets packaging label, showing a quantity of 90 tablets. The label features the RemedyRepack Inc. logo and includes barcode, QR code, and manufacturing information by Aurobindo Pharma, Hyderabad, India. Usage directions refer to the package insert. The label is primarily white with purple accents.*

FDA Label Image

Losartan Potassium 25mg 70518 2132 03

Label for Losartan Potassium 25 mg film-coated tablets, containing 30 tablets. The label includes the NDC number 70518-2132-03, manufacturer information listing Aurobindo Pharma, Hyderabad, India, and repackager RemedyRepack Inc., Indiana. Storage instructions and caution to keep out of reach of children are also shown.*

FDA Label Image

Losartan Potassium 25mg 70518 2132 04

Losartan Potassium 25 mg film-coated tablets bottle label, displaying quantity of 6 tablets. The label shows the product as prescription only with NDC 70518-2132-04. It includes manufacturer information showing Aurobindo Pharma, India, and repackaging by RemedyRepack Inc., Indiana. Storage instructions and a QR code are also visible.*

FDA Label Image

Losartan Potassium 25mg 70518 2132 05

Losartan Potassium 25 mg film-coated tablets, pack of 6. The label shows the product name, strength, dosage form, and quantity. Manufactured by Aurobindo Pharma, India, and repacked by RemedyRepack Inc., Indiana, PA. Includes barcode, NDC 70518-2132-05, and storage instructions at 20-25°C with permitted excursions.*

FDA Label Image

Remedy_label (Remedy Label)

Losartan Potassium 25 mg film-coated tablets packaging label showing a quantity of 30 tablets. The label includes the NDC number 70518-2132-00, repackager RemedyRepack Inc., and states manufacturing by Aurobindo Pharma in Hyderabad, India. Storage instructions specify 20-25°C with permitted excursions. The label cautions to keep medication out of reach of children.*

FDA Label Image

Figure1 (Losartan Fig1)

A line graph comparing the percentage of patients with a primary endpoint over a 66-month study period for Atenolol (dotted line) and Losartan Potassium (solid line). The graph includes an annotation indicating an adjusted risk reduction of 13% with a p-value of 0.021.*

FDA Label Image

Figure2 (Losartan Fig2)

Line graph comparing the percentage of patients with fatal or non-fatal stroke over 66 months between Losartan Potassium (solid line) and Atenolol (dotted line). The study results indicate an adjusted risk reduction of 25% for Losartan Potassium with a p-value of 0.001.*

FDA Label Image

Figure 3 (Losartan Fig3)

A figure titled 'Primary Endpoint Events within Demographic Subgroups' showing comparative hazard ratios for Losartan Potassium and Atenolol. The chart includes data on primary composite events and stroke (fatal/non-fatal) event rates across subgroups such as age, gender, race, ischemic heart disease (ISH), diabetes, and history of cardiovascular disease (CVD). Hazard ratios with confidence intervals are plotted, indicating relative event rates between the two drugs.*

FDA Label Image

Figure-4 (Losartan Fig4)

A line graph comparing the percentage of patients with an event over 48 months between Losartan Potassium and placebo groups. The y-axis shows percentage of patients with events, and the x-axis shows time in months. The graph includes a note indicating a risk reduction of 16.1% with Losartan Potassium and a p-value of 0.022.*

FDA Label Image

Chemical Structure (Losartan Str)

Chemical structure of Losartan Potassium, showing the molecular arrangement including rings, side chains, and the potassium ion (K+).*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.